TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 306577
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole
Study: 19515236
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and vaginal metronidazole
Study: 28544992
Drug: USL261 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: USL261 (both doses)
Study: 19156515
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 40 mg/m² every 4 weeks for 6-9 cycles and weekly trastuzumab (4 mg/kg loading dose, then 2 mg/kg)
Study: 11465562
Drug: Alfentanil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil at a plasma concentration of 100 ng/ml
Study: 7997427
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose of digoxin administered at 24‐h intervals for 7 days (study group, n = 15)
Study: 3375576
Drug: 405 mg
Normalized name: olanzapine 405 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 405 mg elemental calcium as a salt linked to an amino acid precursor
Study: 3375576
Drug: 405 mg
Normalized name: olanzapine 405 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 405 mg CaC12
Study: 3375576
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Ca as Ca gluconolactate and carbonate
Study: 30899530
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 µg/day)
Study: 17391168
Drug: Metformin 1
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1 g twice daily
Study: 14674490
Drug: Microabrasion slurry
Normalized name: SEA SALT 15 g in 100 g / SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL 15 g in 100 g TOPICAL GRANULE [GZE MICRODERMABRASION SCRUB]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microabrasion slurry (Opalustre) for 20 seconds with a load of 200 g
Study: 14674490
Drug: Abrasive cleaning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrasive cleaning paste (Pell-ex) for 20 seconds with a load of 200 g
Study: 19508590
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine (NE) infusion
Study: 3481814
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (ANG II) infusion
Study: 8203510
Drug: Guanadrel (G)
Normalized name: GUANADREL
DrugBank: Guanadrel (DB00226)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guanadrel (G) to suppress SNS activity
Study: 20673244
Drug: Patient-physician agreement
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-physician agreement on final decisions to take medication
Study: 11457560
Drug: TAB9 (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAB9 (0.2 mg)
Study: 11457560
Drug: TAB9 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAB9 (1 mg)
Study: 11457560
Drug: TAB9 (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAB9 (0.2 mg and 1 mg)
Study: 31485880
Drug: Group spiritual
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group spiritual therapy (8 sessions, 45-60 minutes each, twice a week)
Study: 30389671
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) prescriptions (control)
Study: 21457392
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (TA) treatment (750 mg/d for 4 weeks)
Study: 21457392
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral tranexamic acid treatment (Control)
Study: 19042105
Drug: Olanzapine or
Normalized name: olanzapine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine or risperidone treatment after 16 weeks
Study: 19042105
Drug: Baseline (drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (drug naive)
Study: 19644851
Drug: Low-dose D-penicillamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose D-penicillamine
Study: 19644851
Drug: High-dose D-penicillamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose D-penicillamine
Study: 10522184
Drug: Implant-retained overdenture
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implant-retained overdenture (IRO-group, 2 endosseous implants)
Study: 8471413
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg)
Study: 23585009
Drug: Ibutilide 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide 1 mg (repeated if AF/AFL not converted after 10 min)
Study: 23585009
Drug: Propafenone 70
Normalized name: propafenone 70 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 70 mg (repeated if AF/AFL persisted after 10 min)
Study: 15579760
Drug: Pioglitazone (≤45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (≤45 mg/d)
Study: 15579760
Drug: Metformin (≤850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (≤850 mg, three times daily)
Study: 19496943
Drug: Intraduodenal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal administration of 1 mg Ac min(‐1) with varying caloric densities (0.75/1.5/3 kcal min(‐1)) in a 200 mL meal.
Study: 15103751
Drug: Methylprednisolone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (single dose prior to cardiopulmonary bypass)
Study: 12842524
Drug: No steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroid treatment (control group)
Study: 9620251
Drug: Radiotherapy (hypofractionation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (hypofractionation, 5 Gy for fraction, 3-5 doses in one week)
Study: 9620251
Drug: Radiotherapy (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (total dose lower than 34 Gy)
Study: 2223424
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of zopiclone
Study: 2195102
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg of triazolam
Study: 7971743
Drug: Hypnotic-ethanol combinations
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic-ethanol combinations
Study: 7971743
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug intake
Study: 4458774
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three preparations
Study: 23218588
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus iscador
Study: 16443892
Drug: Intensive lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive lifestyle therapy
Study: 23681085
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (500 mg/day)
Study: 19735181
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g n-3 PUFAs
Study: 15108768
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 2 mg/kg/d
Study: 9112067
Drug: Magnesium pyridoxal-5'-phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium pyridoxal-5'-phosphate glutamate (MPPG) 600 mg daily for 8 weeks
Study: 20629109
Drug: Gut-specific nutrients
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gut-specific nutrients (GSNs) administered for 1 month
Study: 11077646
Drug: Monthly combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly combination injectable contraceptive
Study: 8828437
Drug: Maternal magnesium
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal magnesium sulfate administered intrapartum
Study: 1380429
Drug: tropisetron 5mg
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tropisetron 5mg once daily for 5 days
Study: 1380429
Drug: conventional antiemetic
Normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conventional antiemetic drugs
Study: 19934029
Drug: LCZ696 (200-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 (200-1200 mg single-dose; 50-900 mg once daily for 14 days)
Study: 7848353
Drug: Ben-u-ron 500
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ben-u-ron 500 mg suppositories
Study: 7848353
Drug: Ben-u-ron 1000
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ben-u-ron 1000 mg suppositories
Study: 25471688
Drug: Intranasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline (placebo)
Study: 21296449
Drug: 60 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/m2 docetaxel (arm C)
Study: 21296449
Drug: 50 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/m2 escalated to 70 mg/m2 docetaxel (arm D)
Study: 31014270
Drug: Tolvaptan therapy
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan therapy
Study: 17873626
Drug: OPTI-FREE RepleniSH
Normalized name: Opti-Free RepleniSH Multi-Purpose
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPTI-FREE RepleniSH Multi-Purpose Disinfecting Solution (regimen 1)
Study: 17873626
Drug: ReNu MultiPlus
Normalized name: ReNu MultiPlus No-Rub Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReNu MultiPlus Multi-Purpose Solution No Rub Formula (regimen 2)
Study: 17873626
Drug: Complete MoisturePLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete MoisturePLUS Multi-Purpose Solution (regimen 3)
Study: 11730396
Drug: Indinavir, zidovudine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir, zidovudine, and lamivudine therapy
Study: 7740330
Drug: Intravenous vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vinorelbine
Study: 2225410
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg t.i.d.
Study: 2225410
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg and dipyridamole 75 mg t.i.d.
Study: 103467
Drug: 225 mg
Normalized name: tyrosine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg or 450 mg daily of oral papaverine
Study: 28012023
Drug: Subcutaneous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous methotrexate (MTX) administered via auto-injector into the abdomen (MTXAIab)
Study: 28012023
Drug: Subcutaneous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous methotrexate (MTX) administered via auto-injector into the thigh (MTXAIth)
Study: 7945475
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (MTX)
Study: 22943609
Drug: Six-month treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-month treatment program of pharmacotherapy, standardized patient and provider education, and physician and patient counseling
Study: 17599629
Drug: epalrestat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: epalrestat (50 mg/day p.o. ac, t.i.d.)
Study: 21810288
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose oat β‐glucan (3·0 g β‐glucan; oats high ‐ OH)
Study: 15117834
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine challenge (DSMR)
Study: 892957
Drug: Pindolol 5
Normalized name: pindolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 5 mg, three times daily for 6 weeks
Study: 16371411
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² every 3 weeks (3W arm)
Study: 10906101
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C application during DCR surgery (0.2 mg/ml for 30 minutes)
Study: 9289023
Drug: Parenteral group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral group (group 3)
Study: 8513961
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg RU486 (single dose)
Study: 2426419
Drug: Vinblastine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine 0.3 mg/kg/cycle
Study: 23272529
Drug: Adaptogens (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptogens (multiple dose administration, twice daily) plus standard prevention protocol (lifestyle counseling)
Study: 10441602
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of immunotherapy
Study: 10441602
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of immunotherapy
Study: 10441602
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (continuation and discontinuation)
Study: 7801862
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem (bolus dose followed by continuous infusion at 5, 10, and 15 mg/hour)
Study: 7801862
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of diltiazem at 5 mg/hour
Study: 7801862
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of diltiazem at 10 mg/hour
Study: 27707436
Drug: PAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAP therapy
Study: 24479361
Drug: Saline 2
Normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 2 ml, intravenous injection, twice a day (Control)
Study: 24479361
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg (2 ml), intravenous injection, twice a day
Study: 8231902
Drug: 50 micrograms/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms/day transdermal oestradiol (E2) cyclically (n = 20)
Study: 8231902
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day CEE continuously (n = 15)
Study: 8231902
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day CEE and 2.5 mg/day of MPA continuously (n = 20)
Study: 29105855
Drug: Dicloxacillin 1
Normalized name: dicloxacillin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicloxacillin 1 g three times daily for 10 days
Study: 24879757
Drug: Ractopamine hydrochloride
Normalized name: ractopamine hydrochloride
DrugBank: Ractopamine (DB11541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ractopamine hydrochloride (RH; 308 mg·head(‐1)·d(‐1) for 28 d)
Study: 8509523
Drug: Moclobemide (MAO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (MAO inhibitor), fixed-dose schedule for 4 weeks
Study: 3620290
Drug: Sulpiride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (1 mg, 10 mg, 50 mg)
Study: 3620290
Drug: Sulpiride (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (chronic treatment)
Study: 27717552
Drug: IKH‐01 (0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: IKH‐01 (0.035 mg ethinyl estradiol and 1 mg norethisterone)
Study: 19439099
Drug: Narrative Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative Exposure Therapy for children (KIDNET)
Study: 16890599
Drug: Peginterferon-alfa2a (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon-alfa2a (180 microg/wk) plus ribavirin (800 mg/day) for 72 weeks (group B)
Study: 16890599
Drug: Peginterferon-alfa2a (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon-alfa2a (180 microg/wk) plus ribavirin (800 mg/day) for 48 weeks (group A)
Study: 3234469
Drug: Maprotiline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (50 mg b.d. for 15 days)
Study: 29948023
Drug: INTP5 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: INTP5 (3 mg/0.3 ml)
Study: 29948023
Drug: INTP5 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: INTP5 (6 mg/0.6 ml)
Study: 29948023
Drug: Neulasta (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neulasta (3 mg/0.3 ml)
Study: 29948023
Drug: Neulasta (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neulasta (6 mg/0.6 ml)
Study: 23605244
Drug: TLLS+ (transmeatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLLS+ (transmeatal low-power laser stimulation at 5 mW, 650 nM wavelength for 20 min daily and oral betahistine 24 mg twice per day for 10 weeks)
Study: 23605244
Drug: TLLS- (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLLS- (placebo device and oral betahistine 24 mg twice per day for 10 weeks)
Study: 12901286
Drug: 3MU alpha
Normalized name: Alpha Arbutin
DrugBank: alpha-Arbutin (DB14109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3MU alpha N1‐IFN daily for 10 days every 3 months
Study: 12901286
Drug: Reduced dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced dosage of alpha N1‐IFN or stopped interferon therapy or received 30MU dose at 6‐month intervals
Study: 10028075
Drug: Azithromycin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (750 mg loading dose followed by 250 mg/d)
Study: 10028075
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg/d)
Study: 29419337
Drug: Hatha Yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hatha Yoga intervention (twice‐weekly, 60‐minute sessions for 8 weeks)
Study: 23469597
Drug: Dujieqing Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dujieqing Oral Liquid (DJQ) combined with conventional chemotherapy
Study: 18030066
Drug: Clopidogrel 600-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600-mg
Study: 12576937
Drug: Strict normalization
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict normalization of blood glucose (80‐110 mg/dL) with insulin infusion
Study: 12576937
Drug: Conventional approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional approach (blood glucose levels at 180‐200 mg/dL)
Study: 10697394
Drug: Insulin binding
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin binding to erythrocyte receptors in patients with essential hypertension
Study: 10697394
Drug: Insulin concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin concentration in patients with essential hypertension
Study: 10697394
Drug: Insulin degradation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin degradation by erythrocytes
Study: 10697394
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between body weight and insulin concentration
Study: 11870488
Drug: iodixanol 270
Normalized name: IODIXANOL 270mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iodixanol 270 mgI/ml
Study: 8793433
Drug: ioxaglate 320
Normalized name: ioxaglate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioxaglate 320 mgI/ml
Study: 1911585
Drug: Mifepristone 600
Normalized name: Mifepristone 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 600 mg orally 30 h before termination of pregnancy
Study: 29282145
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care without supplemental parenteral nutrition
Study: 18838420
Drug: New Zealand
Normalized name: NEW ZEALAND GREEN MUSSEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Zealand candidate vaccine (epidemic strain NZ98/254, B:4:P1.7b,4)
Study: 12516995
Drug: Meningococcal C
Normalized name: meningococcal conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal C conjugate vaccine
Study: 10509376
Drug: Diazepam (DZP)
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (DZP) 5.0 mg p.o.
Study: 8604671
Drug: Oral riboflavin
Normalized name: riboflavin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral riboflavin (20 mg)
Study: 28207540
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg mifepristone
Study: 24779241
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg mifepristone
Study: 15883741
Drug: Filgrastim 300
Normalized name: FILGRASTIM 300MCG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgrastim 300 microg once daily
Study: 25061714
Drug: SOC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC therapy (Peg-interferon alfa-2b plus ribavirin)
Study: 16968576
Drug: Once-daily ofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily ofloxacin otic solution (0.3%)
Study: 16968576
Drug: Neomycin sulfate/polymyxin
Normalized name: neomycin sulfate/polymyxin B sulfate OPHTHALMIC DROPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension (four times daily)
Study: 11282262
Drug: Sitafloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitafloxacin (400 mg once daily)
Study: 11282262
Drug: Imipenem/cilastatin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/cilastatin (500 mg three times daily)
Study: 8505664
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium diet (total calcium intake of 2200 mg/d)
Study: 8505664
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium diet (240 mg Ca/d)
Study: 20921118
Drug: Adolescent-focused individual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adolescent-focused individual therapy (AFT)
Study: 25440306
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (FBT and AFT)